Fox News medical contributor Nicole Saphier reacted to Johnson & amp; Johnson reporting that their vaccine is not as effective as Pfizer or Moderna. A study by Israel's largest healthcare provider on Sunday found that after participants received two doses of Pfizer's coronavirus vaccine, they saw a 94% drop in symptomatic COVID-19 infections, according to a report. Clalit, the health system that covers most Israelis, compared 600,000 people who received both doses of the Pfizer vaccine against a group of the same size who had matching medical histories and had not yet received the vaccine. The study found that people in the group were also 92% less likely to develop severe illness from the virus after receiving both jabs, according to Reuters. Dry ice is poured into a box containing the Pfizer-BioNTech COVID-19 vaccine as it is prepared to be shipped at the Pfizer Global Supply Kalamazoo manufacturing plant in Portage, Mich., Sunday, Dec. 13, 2020.
A COVID-19 variant first detected in South Africa may evade the protection provided by Pfizer/BioNTech's coronavirus vaccine, a new Israeli study found. A team of researchers at Tel Aviv University and Clalit, Israel's largest health care organization, on Saturday released their study in the online journal MedRXiv. The group examined nearly 400 people diagnosed with COVID-19 after receiving one or two doses of the Pfizer vaccine and compared them with the same number of unvaccinated individuals with coronavirus. The South African variant, referred to as B.1.351, The researchers also found that the variant's prevalence rate was 5.4% among vaccinated patients and 0.7% among unvaccinated patients.
While real-world data like that from Israel is useful, it is subject to variables that can skew the results and which clinical trials try to account for. While the exact order of vaccine recipients may vary by state, most will likely put medical workers and residents of long-term care facilities first. If you want to understand how this decision is getting made, this article will help. Life will return to normal only when society as a whole gains enough protection against the coronavirus. Once countries authorize a vaccine, they'll only be able to vaccinate a few percent of their citizens at most in the first couple months.
Machine learning can be the difference between life and death. The technology, which enables computers teach themselves, is about more than who has the world's biggest AI platform -- or how well a platform evaluates cookie recipes; it could be a tremendous boon for precision medicine, which tailors healthcare to the specifics of individual patients. An individual patient's genome is a massive DNA dataset that has already helped physicians tailor treatment to thousands of patients. Using precision medicine for cancer treatment, for example, involves identifying characteristics that could help predict a specific treatment's effectiveness for a specific patient, OncLive stated on Tuesday. Legacy methods might have based treatment on the cancer's stage, which is a relatively limited indicator of success.